Zaccardelli David's Form 4 filing
Verona Pharma plcVRNA · filed May 5, 2025
- Accession no.
- 0001104659-25-044530
- Filed
- May 5, 2025
- Trade date
- May 1-2, 2025
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Checked
This filing lists 4 non-derivative transactions and 1 derivative transaction. Open-market sales total $5.31M. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Zaccardelli DavidCIK 0001627642 | Director, Officer (President and CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 1, 2025 | Ordinary Shares | SSaleDisposed | −108,272 | $8.95F3 | −$969,034.4 | 14,268,904 | Direct | |
| May 1, 2025 | Ordinary Shares | MOption exerciseAcquired | +200,000 | –F4 | – | 14,468,904 | Direct | |
| May 1, 2025 | Ordinary Shares | SSaleDisposed | −78,736 | $8.95F3 | −$704,687.2 | 14,390,168 | Direct | |
| May 2, 2025 | Ordinary Shares | SSaleDisposed | −400,000 | $9.09F6 | −$3,636,000 | 13,990,168 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 1, 2025 | Ordinary Shares | MOption exerciseDisposed | −200,000 | $0.00 | $0 | 1,000,000 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F3
The price reported represents the sale price of the ADSs divided by eight (8).
Referenced by the price of 2 transactions in Table I.
- F4
Represents an award of performance-based Restricted Share Units ("RSUs") covering American Depositary Shares ("ADSs"), which is presented in terms of the equivalent number of Ordinary Shares underlying the ADSs. Each RSU represents a contingent right to receive one (1) ADS of the Issuer. Each ADS represents eight (8) Ordinary Shares of the Issuer. The RSUs have no expiration date.
Referenced by the price of 1 transaction in Table I.
- F6
The price reported represents a weighted average price of the ADSs divided by eight (8). The securities were sold in multiple transactions at prices ranging from $8.91 to $9.2213 per Ordinary Share, inclusive (or $71.28 to $73.77 per ADS, inclusive). The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.